{
 "ticker": "BBP",
 "name": "Virtus Biotech ETF",
 "issuer": "not established",
 "desk": "themes",
 "url": "https://etfiq.com/funds/BBP",
 "html": "https://etfiq.com/funds/BBP",
 "markdown": "https://etfiq.com/funds/BBP.md",
 "as_of": "2026-09-11",
 "verdict": "BBP holds 60 stocks, and 88% of its weight is outside the S&P 500.",
 "key_facts": [
  {
   "key": "already_in_the_s_p_500",
   "label": "Already in the S&P 500",
   "value": "12.4%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "BBP, already in the S&P 500: 12.4%, as of Sep 11, 2026."
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "99.0%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "BBP, active share vs the S&P 500: 99.0%, as of Sep 11, 2026."
  },
  {
   "key": "top_ten_holdings",
   "label": "Top ten holdings",
   "value": "25.7%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "BBP, top ten holdings: 25.7%, as of Sep 11, 2026."
  },
  {
   "key": "total_return_1_year",
   "label": "Total return, 1 year",
   "value": "+47.0%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "BBP, total return, 1 year: +47.0%, as of Sep 11, 2026."
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$59m",
   "source": "SEC filing, whole fund, as filed for Apr 30, 2026",
   "as_of": "2026-09-11",
   "sentence": "BBP, net assets: $59m (SEC filing, whole fund, as filed for Apr 30, 2026)."
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.34%",
   "source": "485BPOS XBRL, Feb 27, 2026",
   "as_of": "2026-09-11",
   "sentence": "BBP, expense ratio: 0.34% (485BPOS XBRL, Feb 27, 2026)."
  }
 ],
 "fields": [
  {
   "key": "theme",
   "label": "Theme",
   "value": "Biotech and genomics",
   "source": "ETFIQ, editorial"
  },
  {
   "key": "launched",
   "label": "Launched",
   "value": "Dec 17, 2014",
   "source": null
  },
  {
   "key": "already_in_the_s_p_500_by_weight",
   "label": "Already in the S&P 500, by weight",
   "value": "12.4%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "99.0%",
   "source": "ETFIQ"
  },
  {
   "key": "already_in_the_nasdaq_100_by_weight",
   "label": "Already in the Nasdaq-100, by weight",
   "value": "8.9%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_nasdaq_100",
   "label": "Active share vs the Nasdaq-100",
   "value": "97.4%",
   "source": "ETFIQ"
  },
  {
   "key": "top_ten_holdings_weight",
   "label": "Top ten holdings weight",
   "value": "25.7%",
   "source": null
  },
  {
   "key": "holdings",
   "label": "Holdings",
   "value": "60",
   "source": null
  },
  {
   "key": "holdings_as_of",
   "label": "Holdings as of",
   "value": "Apr 30, 2026",
   "source": "SEC N-PORT"
  },
  {
   "key": "top_holdings",
   "label": "Top holdings",
   "value": "IMMUNITYBIO INC 4.8%, APELLIS PHARMACEUTICALS INC 2.6%, KALVISTA PHARMACEUTICALS INC 2.5%, MODERNA INC 2.5%, IOVANCE BIOTHERAPEUTICS INC 2.5%, MIRUM PHARMACEUTICALS INC 2.4%, AXSOME THERAPEUTICS INC 2.2%, KINIKSA PHARMACEUTICALS INTERNATIONAL PLC 2.1%, ROIVANT SCIENCES LTD 2.1%, ZAI LAB LTD 1.9%",
   "source": null
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$59m",
   "source": "SEC filing, whole fund, as filed for Apr 30, 2026"
  },
  {
   "key": "below_its_all_time_high",
   "label": "Below its all-time high",
   "value": "\u22125.9%",
   "source": "ETFIQ"
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.34%",
   "source": "485BPOS XBRL, Feb 27, 2026"
  },
  {
   "key": "fee_for_the_part_that_differs_from_the_s_p_500_active_expense_ratio",
   "label": "Fee for the part that differs from the S&P 500, active expense ratio",
   "value": "0.34%",
   "source": "ETFIQ"
  },
  {
   "key": "closest_funds_by_holdings_overlap",
   "label": "Closest funds by holdings overlap",
   "value": "IBBQ 35%, PBE 34%, FBT 30%, WDNA 26%, HELX 24%",
   "source": null
  }
 ],
 "periods": [
  {
   "window": "3 months",
   "Total return": "+18.7%",
   "S&P 500": "+3.3%",
   "Gap to S&P 500": "+15.4 pts",
   "Gap to Nasdaq-100": "+19.5 pts"
  },
  {
   "window": "6 months",
   "Total return": "+27.3%",
   "S&P 500": "+16.0%",
   "Gap to S&P 500": "+11.3 pts",
   "Gap to Nasdaq-100": "+6.7 pts"
  },
  {
   "window": "1 year",
   "Total return": "+47.0%",
   "S&P 500": "+17.5%",
   "Gap to S&P 500": "+29.5 pts",
   "Gap to Nasdaq-100": "+24.1 pts"
  },
  {
   "window": "3 years",
   "Total return": "+94.7%",
   "S&P 500": "+77.9%",
   "Gap to S&P 500": "+16.8 pts",
   "Gap to Nasdaq-100": "\u22120.4 pts"
  },
  {
   "window": "Since launch",
   "Total return": "+303.1%",
   "S&P 500": "+361.5%",
   "Gap to S&P 500": "\u221258.4 pts",
   "Gap to Nasdaq-100": "\u2212365.4 pts"
  }
 ],
 "questions": [
  {
   "q": "How much of BBP is in S&P 500 companies?",
   "a": "By its holdings filed for Apr 30, 2026, 12% of BBP by weight is stocks the S&P 500 already holds. Its active share against the index is 99%, so that share is the part doing something different."
  },
  {
   "q": "What does BBP hold?",
   "a": "60 positions as filed for Apr 30, 2026, with the top ten at 26% of the fund. The largest are IMMUNITYBIO INC at 4.8%, APELLIS PHARMACEUTICALS INC at 2.6%, KALVISTA PHARMACEUTICALS INC at 2.5%."
  },
  {
   "q": "Has BBP beaten the S&P 500?",
   "a": "Over the year to Sep 11, 2026 BBP returned +47.0% with distributions reinvested, against +17.5% for the S&P 500, so it finished ahead of the index by 29.5 points."
  },
  {
   "q": "What does BBP cost?",
   "a": "The prospectus expense ratio is 0.34% a year. Because 99% of the fund differs from the S&P 500, the fee on that differing part works out at 0.34%."
  }
 ],
 "generated": "2026-09-13",
 "license": "Free to use with attribution. ETFIQ (etfiq.com)."
}